PSORIATIC ARTHRITIS TREATMENT MARKET TO SURPASS USD 25,375.6 MILLION BY 2034, GROWING AT 7.8% CAGR

Psoriatic Arthritis Treatment Market to Surpass USD 25,375.6 Million by 2034, Growing at 7.8% CAGR

Psoriatic Arthritis Treatment Market to Surpass USD 25,375.6 Million by 2034, Growing at 7.8% CAGR

Blog Article

The global psoriatic arthritis (PsA) treatment market is projected to experience substantial growth, with its valuation expected to rise from USD 11,973.7 million in 2024 to USD 25,375.6 million by 2034 , reflecting a compound annual growth rate (CAGR) of 7.8% during the forecast period.

Psoriatic arthritis, a chronic inflammatory condition that affects individuals with psoriasis, continues to drive demand for effective treatment options. With approximately 125 million people worldwide suffering from psoriasis, the prevalence of PsA is climbing steadily, further underscoring the critical need for therapeutic solutions. The growing patient population is a significant factor propelling the market’s expansion.

The treatment landscape for PsA includes biologic therapies , nonsteroidal anti-inflammatory drugs (NSAIDs) , disease-modifying antirheumatic drugs (DMARDs) , and innovative targeted therapies. Advancements in biologics and small molecule drugs are improving patient outcomes and fueling market growth. The increasing awareness of PsA and improved diagnostic capabilities are also contributing to higher treatment adoption rates globally.

A Comprehensive Full Report - https://www.futuremarketinsights.com/reports/psoriatic-arthritis-psa-treatment-market

Key Highlights :


  1. The psoriatic arthritis treatment market is projected to grow at a CAGR of 7.8% from 2024 to 2034.

  2. Market valuation is expected to rise from USD 11,973.7 million in 2024 to USD 25,375.6 million by 2034 .

  3. Approximately 125 million people globally are affected by psoriasis, driving the need for effective PsA treatments.

  4. Innovations in biologic therapies and targeted treatments are enhancing patient care and supporting market growth.


As the prevalence of psoriatic arthritis continues to rise, the market for related treatments is expected to thrive, offering new and improved therapeutic options that enhance the quality of life for millions of patients worldwide.

Growth Drivers

  1. Increasing Prevalence of Psoriasis : Approximately  125 million people worldwide  are affected by psoriasis, leading to a higher demand for effective treatments for associated conditions like psoriatic arthritis.

  2. Aging Population : The global population is aging rapidly, resulting in more individuals developing psoriatic arthritis, thus expanding the patient pool.

  3. Advancements in Treatment Options : The market benefits from a wide variety of treatment options, including biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and disease-modifying anti-rheumatic drugs (DMARDs), which enhance patient management.

  4. Regulatory Approvals : Recent approvals of new therapies by regulatory bodies like the FDA are facilitating market growth.


Regional Insights

  • North America : Dominates the market due to a well-established healthcare system and high prevalence of psoriatic arthritis.

  • Europe and Asia-Pacific : Expected to show significant growth driven by increasing awareness and improved healthcare access.


Competitive Landscape in the Psoriatic Arthritis (PsA) Treatment Market

The development of new drugs remains a priority for players. In addition, collaborative strategies are also part of the vision. Partnerships with public bodies are sought to raise awareness about the disease.

The need for developing novel drug options is evident when looking at an industry giant like copyright Inc. The company also partners with other healthcare sector players for the development of new drugs. Johnson and Johnson also concentrate on new drug development, investing significant amounts into trials.

Recent Developments in the Psoriatic Arthritis (PsA) Treatment Market

  • In September 2023, Wellmin Health, in collaboration with the non-profit organization Versus Arthritis, launched the Pathway platform. It is a program developed to help patients with arthritis, including psoriatic arthritis.

  • In February 2024, Biocon Biologics announced that it had reached an agreement with Janssen Biotech Inc. and Johnson & Johnson to commercialize the drug Bmab 1200.


Key Companies in the Psoriatic Arthritis (PsA) Treatment Market

Key companies in the industry include copyright Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, UCB S.A., Eli Lilly & Co, Novartis AG, Celgene Corporation, and AstraZeneca PLC.

Report this page